OM1 expands mental health network to over six million patients, enhancing real-world evidence and personalized care capabilities

OM1 has added more than one million patients to its mental health network, expanding its ability to generate real-world evidence (RWE) for conditions such as depression, schizophrenia, and bipolar disorder.

OM1, a health technology company specializing in personalized medicine, evidence generation, and RWE research using advanced AI and longitudinal data, has expanded its specialty mental health network, bringing the total number of patients to more than six million. The larger network is intended to support the generation of timely and representative real-world data (RWD) for use in research and healthcare-related analyses.

The expanded network enhances OM1’s PremiOM™ datasets, which focus on major depressive disorder (MDD), schizophrenia (SCZ), and bipolar I disorder (BP1). These research-ready datasets integrate medical and pharmacy claims, curated outcomes, and both structured and unstructured clinical data, enabling more detailed subgroup analysis and faster access to real-world insights.

Dr Carl Marci, Chief Clinical Officer and Managing Director of Mental Health and Neuroscience at OM1, noted the importance of the expanded cohort:

“Access to large, longitudinal, and representative mental health cohorts is critical for uncovering real-world patterns and insights that smaller cohorts often miss. With over six million patients followed by psychiatrists along with other mental health providers, including clinical notes, OM1 can leverage its advanced AI to enrich condition-specific datasets and surface deeper insights into disease progression and treatment response, helping to realize the full potential of RWD in mental health.”

The larger network provides a significant increase in the number of patients with deep clinical data and longitudinal follow-up, enabling more robust real-world studies and more detailed subgroup analysis. OM1’s AI tools apply validated models to unstructured clinical notes to extract and enhance important mental health endpoints, including PHQ-9 scores, CGI-I ratings, and key symptoms such as anhedonia, trouble concentrating, insomnia, fatigue, and suicidality. These expanded capabilities support a greater ability to understand and predict treatment-resistant depression and other complex mental health conditions.

Given that fewer than a third of psychiatry and mental health practices currently use measurement-based care, valuable clinical insights are often not captured in structured data. OM1’s technology helps address this gap by analyzing unstructured content within its Real-World Data Cloud (RWDC), which includes data from more than 350 million patients.